Genetic testing firm 23andMe agreed to be acquired by a nonprofit led by co-founder Anne Wojcicki for $305 million, prevailing in a final bidding round over Regeneron. This transaction concludes a bankruptcy auction, with the company seeking the best outcome for shareholders amid restructuring. The acquisition by Wojcicki's TTAM Research Institute signals a strategic shift toward nonprofit research models in consumer genomics.